Literature DB >> 21282419

Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.

Adele L McCormick1, Chris M Parry, Anne Crombe, Ruth L Goodall, Ravindra K Gupta, Pontiano Kaleebu, Cissy Kityo, Michael Chirara, Greg J Towers, Deenan Pillay.   

Abstract

We investigated the effect of N348I alone and with M184V on nonnucleoside reverse transcriptase inhibitor (NNRTI) drug susceptibility and replicative capacity in B and non-B HIV-1 isolates. N348I reduced the susceptibility to all NNRTI drugs across subtypes. The replication capacity of all viruses in a variety of cell lines was impaired by N348I. Interestingly, the N348I and M184V double mutation compensated for the reduced NNRTI drug susceptibility observed in the N348I single mutant and marginally improved viral replicative capacity.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21282419      PMCID： PMC3067126          DOI： 10.1128/AAC.01197-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.

Authors:  Mia J Biondi; Greg L Beilhartz; Suzanne McCormick; Matthias Götte
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

2.  Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.

Authors:  Viktor von Wyl; Maryam Ehteshami; Jori Symons; Philippe Bürgisser; Monique Nijhuis; Lisa M Demeter; Sabine Yerly; Jürg Böni; Thomas Klimkait; Rob Schuurman; Bruno Ledergerber; Matthias Götte; Huldrych F Günthard
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

3.  Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Authors:  Jeannette M Whitcomb; Wei Huang; Kay Limoli; Ellen Paxinos; Terri Wrin; Gail Skowron; Steven G Deeks; Michael Bates; Nicholas S Hellmann; Christos J Petropoulos
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

4.  Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone.

Authors:  T Ndung'u; B Renjifo; M Essex
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection.

Authors:  S D Frost; M Nijhuis; R Schuurman; C A Boucher; A J Brown
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.

Authors:  Nicolas Sluis-Cremer; Katie Moore; Jessica Radzio; Secondo Sonza; Gilda Tachedjian
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

7.  Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients.

Authors:  Anne-Genevieve Marcelin; Philippe Flandre; Diane Descamps; Laurence Morand-Joubert; Charlotte Charpentier; Jacques Izopet; Mary-Anne Trabaud; Henia Saoudin; Constance Delaugerre; Catherine Tamalet; Jacqueline Cottalorda; Magali Bouvier-Alias; Dominique Bettinger; Georges Dos Santos; Annick Ruffault; Chakib Alloui; Cecile Henquell; Sylvie Rogez; Francis Barin; Anne Signori-Schmuck; Sophie Vallet; Bernard Masquelier; Vincent Calvez
Journal:  Antimicrob Agents Chemother       Date:  2009-11-09       Impact factor: 5.191

8.  Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.

Authors:  Eva Poveda; Carolina Garrido; Carmen de Mendoza; Angélica Corral; Julio Cobo; Juan González-Lahoz; Vincent Soriano
Journal:  J Antimicrob Chemother       Date:  2007-10-03       Impact factor: 5.790

9.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

10.  Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.

Authors:  Chris M Parry; Arinder Kohli; Christine J Boinett; Greg J Towers; Adele L McCormick; Deenan Pillay
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103
View more
  17 in total

1.  Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.

Authors:  Eugene L Asahchop; Mark A Wainberg; Richard D Sloan; Cécile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

2.  Compensatory role of double mutation N348I/M184V on nevirapine binding landscape: insight from molecular dynamics simulation.

Authors:  Wilson Karubiu; Soumendranath Bhakat; Mahmoud E S Soliman
Journal:  Protein J       Date:  2014-10       Impact factor: 2.371

3.  N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.

Authors:  Soo Huey Yap; Brian D Herman; Jessica Radzio; Nicolas Sluis-Cremer; Gilda Tachedjian
Journal:  J Acquir Immune Defic Syndr       Date:  2012-10-01       Impact factor: 3.731

4.  Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

Authors:  Jessica H Brehm; Dianna L Koontz; Carole L Wallis; Kathleen A Shutt; Ian Sanne; Robin Wood; James A McIntyre; Wendy S Stevens; Nicolas Sluis-Cremer; John W Mellors
Journal:  Clin Infect Dis       Date:  2012-05-22       Impact factor: 9.079

5.  Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Authors:  Jan Weber; Ana C Vazquez; Dane Winner; Justine D Rose; Doug Wylie; Ariel M Rhea; Kenneth Henry; Jennifer Pappas; Alison Wright; Nizar Mohamed; Richard Gibson; Benigno Rodriguez; Vicente Soriano; Kevin King; Eric J Arts; Paul D Olivo; Miguel E Quiñones-Mateu
Journal:  Antimicrob Agents Chemother       Date:  2011-05-31       Impact factor: 5.191

6.  Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Authors:  Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak
Journal:  Virology       Date:  2012-10-13       Impact factor: 3.616

Review 7.  Are subtype differences important in HIV drug resistance?

Authors:  R J Lessells; D K Katzenstein; T de Oliveira
Journal:  Curr Opin Virol       Date:  2012-09-21       Impact factor: 7.090

8.  The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Maureen Oliveira; Yingshan Han; Yudong Quan; Veronica Zanichelli; Mark A Wainberg
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

Review 9.  The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance.

Authors:  Mark A Wainberg
Journal:  Scientifica (Cairo)       Date:  2012-12-31

10.  HIV-1 Genetic Variability and Clinical Implications.

Authors:  Maria Mercedes Santoro; Carlo Federico Perno
Journal:  ISRN Microbiol       Date:  2013-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.